Operations of Industrial Affairs Site Sanofi-aventis

Abstract

Number one Pharmaceutical Company in France and in Europe, number three worldwide sanofi-aventis has been positioned as a key player in the healthcare. The Group was set up more than 30 years ago. Their business consists of discovering, developing and providing physicians and patients throughout the world whit innovative, effective, well-tolerated and high-quality treatments, whilst maintaining the economic performance levels that will permit them to continue this undertaking. As a global industry leader Sanofi-aventis seek to conquer and prevent disease by bringing to market innovative pharmaceuticals, vaccines, therapeutic proteins and diagnostics. Aventis pharma was created as a part of the 1999 business combination of Hoechst and Rhone-Poulenc to form Aventis SA, one of the world's leading life sciences companies. Aventis Pharma concentrates its efforts on strategic brands that meet growing patient needs and contribute to a long-term sales growth. With 2001 sales of 15.168 billion euro (excluding sales of diagnostics), Aventis Pharma contributes three-quarters of the life sciences sales of Aventis SA. The Aventis Pharma prescription drug business is investing about 2.98 billion euro a year in Drug Innovation and Approval, one of the industry's largest R&D budgets.